<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240712222744&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240712222744&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 13 Jul 2024 02:27:45 +0000</lastbuilddate>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Intracoronary polarimetric signatures of exercise-induced vasospastic angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38995856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae447. doi: 10.1093/eurheartj/ehae447. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38995856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38995856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae447>10.1093/eurheartj/ehae447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38995856</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Takenobu Shimada</dc:creator>
<dc:creator>Naoki Fujisawa</dc:creator>
<dc:creator>Kenichiro Otsuka</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intracoronary polarimetric signatures of exercise-induced vasospastic angina</dc:title>
<dc:identifier>pmid:38995856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae447</dc:identifier>
</item>
<item>
<title>Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38995853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Infancy-onset 20-year dietary intervention had favourable effects on the retinal microvasculature in young adulthood. Several lifelong cumulative cardiovascular risk factors were independently associated with retinal microvascular structure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae423. doi: 10.1093/eurheartj/ehae423. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Retinal microvasculature characteristics predict cardiovascular morbidity and mortality. This study investigated associations of lifelong cardiovascular risk factors and effects of dietary intervention on retinal microvasculature in young adulthood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The cohort is derived from the longitudinal Special Turku Coronary Risk Factor Intervention Project study. The Special Turku Coronary Risk Factor Intervention Project is a 20-year infancy-onset randomized controlled dietary intervention study with frequent study visits and follow-up extending to age 26 years. The dietary intervention aimed at a heart-healthy diet. Fundus photographs were taken at the 26-year follow-up, and microvascular measures [arteriolar and venular diameters, tortuosity (simple and curvature) and fractal dimensions] were derived (n = 486). Cumulative exposure as the area under the curve for cardiovascular risk factors and dietary components was determined for the longest available time period (e.g. from age 7 months to 26 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The dietary intervention had a favourable effect on retinal microvasculature resulting in less tortuous arterioles and venules and increased arteriolar fractal dimension in the intervention group when compared with the control group. The intervention effects were found even when controlled for the cumulative cardiovascular risk factors. Reduced lifelong cumulative intake of saturated fats, main target of the intervention, was also associated with less tortuous venules. Several lifelong cumulative risk factors were independently associated with the retinal microvascular measures, e.g. cumulative systolic blood pressure with narrower arterioles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Infancy-onset 20-year dietary intervention had favourable effects on the retinal microvasculature in young adulthood. Several lifelong cumulative cardiovascular risk factors were independently associated with retinal microvascular structure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38995853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38995853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae423>10.1093/eurheartj/ehae423</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38995853</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Oskari Repo</dc:creator>
<dc:creator>Markus Juonala</dc:creator>
<dc:creator>Harri Niinikoski</dc:creator>
<dc:creator>Suvi Rovio</dc:creator>
<dc:creator>Juha Mykkänen</dc:creator>
<dc:creator>Hanna Lagström</dc:creator>
<dc:creator>Carol Y Cheung</dc:creator>
<dc:creator>Dawei Yang</dc:creator>
<dc:creator>Hanna Vaahtoranta-Lehtonen</dc:creator>
<dc:creator>Antti Jula</dc:creator>
<dc:creator>Jaakko Nevalainen</dc:creator>
<dc:creator>Tapani Rönnemaa</dc:creator>
<dc:creator>Jorma Viikari</dc:creator>
<dc:creator>Olli Raitakari</dc:creator>
<dc:creator>Robyn Tapp</dc:creator>
<dc:creator>Katja Pahkala</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature</dc:title>
<dc:identifier>pmid:38995853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae423</dc:identifier>
</item>
<item>
<title>A fresh look to residual risk: triglycerides, apolipoprotein B, and sweeteners</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38995664/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12;45(27):2347-2351. doi: 10.1093/eurheartj/ehae444.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38995664/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38995664</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae444>10.1093/eurheartj/ehae444</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38995664</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A fresh look to residual risk: triglycerides, apolipoprotein B, and sweeteners</dc:title>
<dc:identifier>pmid:38995664</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae444</dc:identifier>
</item>
<item>
<title>Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38993086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae378. doi: 10.1093/eurheartj/ehae378. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Home treatment is considered safe in acute pulmonary embolism (PE) patients selected by a validated triage tool (e.g. simplified PE severity index score or Hestia rule), but there is uncertainty regarding the applicability in underrepresented subgroups. The aim was to evaluate the safety of home treatment by performing an individual patient-level data meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Ten prospective cohort studies or randomized controlled trials were identified in a systematic search, totalling 2694 PE patients treated at home (discharged within 24 h) and identified by a predefined triage tool. The 14- and 30-day incidences of all-cause mortality and adverse events (combined endpoint of recurrent venous thromboembolism, major bleeding, and/or all-cause mortality) were evaluated. The relative risk (RR) for 14- and 30-day mortalities and adverse events is calculated in subgroups using a random effects model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The 14- and 30-day mortalities were 0.11% [95% confidence interval (CI) 0.0-0.24, I2 = 0) and 0.30% (95% CI 0.09-0.51, I2 = 0). The 14- and 30-day incidences of adverse events were 0.56% (95% CI 0.28-0.84, I2 = 0) and 1.2% (95% CI 0.79-1.6, I2 = 0). Cancer was associated with increased 30-day mortality [RR 4.9; 95% prediction interval (PI) 2.7-9.1; I2 = 0]. Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal (N-terminal pro-)B-type natriuretic peptide [(NT-pro)BNP] at presentation were associated with an increased incidence of 14-day adverse events [RR 3.5 (95% PI 1.5-7.9, I2 = 0), 2.5 (95% PI 1.3-4.9, I2 = 0), and 3.9 (95% PI 1.6-9.8, I2 = 0), respectively], but not mortality. At 30 days, cancer, abnormal troponin, and abnormal (NT-pro)BNP were associated with an increased incidence of adverse events [RR 2.7 (95% PI 1.4-5.2, I2 = 0), 2.9 (95% PI 1.5-5.7, I2 = 0), and 3.3 (95% PI 1.6-7.1, I2 = 0), respectively].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38993086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38993086</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae378>10.1093/eurheartj/ehae378</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38993086</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Dieuwke Luijten</dc:creator>
<dc:creator>Delphine Douillet</dc:creator>
<dc:creator>Kim Luijken</dc:creator>
<dc:creator>Cecile Tromeur</dc:creator>
<dc:creator>Andrea Penaloza</dc:creator>
<dc:creator>Olivier Hugli</dc:creator>
<dc:creator>Drahomir Aujesky</dc:creator>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Joseph R Bledsoe</dc:creator>
<dc:creator>Kyle E Chang</dc:creator>
<dc:creator>Francis Couturaud</dc:creator>
<dc:creator>Paul L den Exter</dc:creator>
<dc:creator>Carme Font</dc:creator>
<dc:creator>Menno V Huisman</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Christopher Kabrhel</dc:creator>
<dc:creator>Jeffrey A Kline</dc:creator>
<dc:creator>Stavros Konstantinides</dc:creator>
<dc:creator>Thijs van Mens</dc:creator>
<dc:creator>Remedios Otero</dc:creator>
<dc:creator>W Frank Peacock</dc:creator>
<dc:creator>Olivier Sanchez</dc:creator>
<dc:creator>William B Stubblefield</dc:creator>
<dc:creator>Luca Valerio</dc:creator>
<dc:creator>David R Vinson</dc:creator>
<dc:creator>Philip Wells</dc:creator>
<dc:creator>Maarten van Smeden</dc:creator>
<dc:creator>Pierre-Marie Roy</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis</dc:title>
<dc:identifier>pmid:38993086</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae378</dc:identifier>
</item>
<item>
<title>Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38993069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae335. doi: 10.1093/eurheartj/ehae335. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0-21 days following COVID-19 vaccination.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77-1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39-2.54) following vaccination.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38993069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38993069</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae335>10.1093/eurheartj/ehae335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38993069</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>You-Jung Choi</dc:creator>
<dc:creator>Jaehyun Lim</dc:creator>
<dc:creator>Sungho Bea</dc:creator>
<dc:creator>Jieun Lee</dc:creator>
<dc:creator>Jah Yeon Choi</dc:creator>
<dc:creator>Seung Young Rho</dc:creator>
<dc:creator>Dae-In Lee</dc:creator>
<dc:creator>Jin Oh Na</dc:creator>
<dc:creator>Hyung-Kwan Kim</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study</dc:title>
<dc:identifier>pmid:38993069</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae335</dc:identifier>
</item>
<item>
<title>Thrombotic risks associated with COVID-19 vaccination in atrial fibrillation or atrial flutter: no reason for alarm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38993061/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae336. doi: 10.1093/eurheartj/ehae336. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38993061/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38993061</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae336>10.1093/eurheartj/ehae336</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38993061</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean M Connors</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thrombotic risks associated with COVID-19 vaccination in atrial fibrillation or atrial flutter: no reason for alarm</dc:title>
<dc:identifier>pmid:38993061</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae336</dc:identifier>
</item>
<item>
<title>Cardiovascular effects of climate change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38992906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12:ehae401. doi: 10.1093/eurheartj/ehae401. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38992906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38992906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae401>10.1093/eurheartj/ehae401</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38992906</guid>
<pubDate>Fri, 12 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-07-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular effects of climate change</dc:title>
<dc:identifier>pmid:38992906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae401</dc:identifier>
</item>
<item>
<title>Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38991046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Igfbp7 produced by senescent ECs causes cardiac dysfunction and vaccine therapy targeting Igfbp7 may be useful to prevent the development of heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.064719. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The heart comprises many types of cells such as cardiomyocytes, endothelial cells (ECs), fibroblasts, smooth muscle cells, pericytes, and blood cells. Every cell type responds to various stressors (eg, hemodynamic overload and ischemia) and changes its properties and interrelationships among cells. To date, heart failure research has focused mainly on cardiomyocytes; however, other types of cells and their cell-to-cell interactions might also be important in the pathogenesis of heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pressure overload was imposed on mice by transverse aortic constriction and the vascular structure of the heart was examined using a tissue transparency technique. Functional and molecular analyses including single-cell RNA sequencing were performed on the hearts of wild-type mice and EC-specific gene knockout mice. Metabolites in heart tissue were measured by capillary electrophoresis-time of flight-mass spectrometry system. The vaccine was prepared by conjugating the synthesized epitope peptides with keyhole limpet hemocyanin and administered to mice with aluminum hydroxide as an adjuvant. Tissue samples from heart failure patients were used for single-nucleus RNA sequencing to examine gene expression in ECs and perform pathway analysis in cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Pressure overload induced the development of intricately entwined blood vessels in murine hearts, leading to the accumulation of replication stress and DNA damage in cardiac ECs. Inhibition of cell proliferation by a cyclin-dependent kinase inhibitor reduced DNA damage in ECs and ameliorated transverse aortic constriction-induced cardiac dysfunction. Single-cell RNA sequencing analysis revealed upregulation of <i>Igfbp7</i> (insulin-like growth factor-binding protein 7) expression in the senescent ECs and downregulation of insulin signaling and oxidative phosphorylation in cardiomyocytes of murine and human failing hearts. Overexpression of <i>Igfbp7</i> in the murine heart using AAV9 (adeno-associated virus serotype 9) exacerbated cardiac dysfunction, while EC-specific deletion of <i>Igfbp7</i> and the vaccine targeting Igfbp7 ameliorated cardiac dysfunction with increased oxidative phosphorylation in cardiomyocytes under pressure overload.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: <i>Igfbp7</i> produced by senescent ECs causes cardiac dysfunction and vaccine therapy targeting Igfbp7 may be useful to prevent the development of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38991046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38991046</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064719>10.1161/CIRCULATIONAHA.123.064719</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38991046</guid>
<pubDate>Thu, 11 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Manami Katoh</dc:creator>
<dc:creator>Seitaro Nomura</dc:creator>
<dc:creator>Shintaro Yamada</dc:creator>
<dc:creator>Masamichi Ito</dc:creator>
<dc:creator>Hiroki Hayashi</dc:creator>
<dc:creator>Mikako Katagiri</dc:creator>
<dc:creator>Tuolisi Heryed</dc:creator>
<dc:creator>Takayuki Fujiwara</dc:creator>
<dc:creator>Norifumi Takeda</dc:creator>
<dc:creator>Miyuki Nishida</dc:creator>
<dc:creator>Maki Sugaya</dc:creator>
<dc:creator>Miki Kato</dc:creator>
<dc:creator>Tsuyoshi Osawa</dc:creator>
<dc:creator>Hiroyuki Abe</dc:creator>
<dc:creator>Yoshitaka Sakurai</dc:creator>
<dc:creator>Toshiyuki Ko</dc:creator>
<dc:creator>Kanna Fujita</dc:creator>
<dc:creator>Bo Zhang</dc:creator>
<dc:creator>Satoshi Hatsuse</dc:creator>
<dc:creator>Takanobu Yamada</dc:creator>
<dc:creator>Shunsuke Inoue</dc:creator>
<dc:creator>Zhehao Dai</dc:creator>
<dc:creator>Masayuki Kubota</dc:creator>
<dc:creator>Kousuke Sawami</dc:creator>
<dc:creator>Minoru Ono</dc:creator>
<dc:creator>Hiroyuki Morita</dc:creator>
<dc:creator>Yoshiaki Kubota</dc:creator>
<dc:creator>Seiya Mizuno</dc:creator>
<dc:creator>Satoru Takahashi</dc:creator>
<dc:creator>Makoto Nakanishi</dc:creator>
<dc:creator>Tetsuo Ushiku</dc:creator>
<dc:creator>Hironori Nakagami</dc:creator>
<dc:creator>Hiroyuki Aburatani</dc:creator>
<dc:creator>Issei Komuro</dc:creator>
<dc:date>2024-07-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7</dc:title>
<dc:identifier>pmid:38991046</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064719</dc:identifier>
</item>
<item>
<title>RNF149 Destabilizes IFNGR1 in Macrophages to Favor Post-Infarction Cardiac Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38989590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings highlight the significance of RNF149 as a molecular brake on macrophage response to MI and uncover a macrophage-intrinsic posttranslational mechanism essential for maintaining immune homeostasis and facilitating cardiac repair following MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 11. doi: 10.1161/CIRCRESAHA.123.324023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Macrophage-driven inflammation critically involves in cardiac injury and repair following myocardial infarction (MI). However, the intrinsic mechanisms that halt the immune response of macrophages, which is critical to preserve homeostasis and effective infarct repair, remain to be fully defined. Here, we aimed to determine the ubiquitination-mediated regulatory effects on averting exaggerated inflammatory responses in cardiac macrophages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used transcriptome analysis of mouse cardiac macrophages and bone marrow-derived macrophages to identify the E3 ubiquitin ligase RNF149 (RING finger protein 149) as a modulator of macrophage response to MI. Employing loss-of-function methodologies, bone marrow transplantation approaches, and adenovirus-mediated RNF149 overexpression in macrophages, we elucidated the functional role of RNF149 in MI. We explored the underlying mechanisms through flow cytometry, transcriptome analysis, immunoprecipitation/mass spectrometry analysis, and functional experiments. RNF149 expression was measured in the cardiac tissues of patients with acute MI and healthy controls.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RNF149 was highly expressed in murine and human cardiac macrophages at the early phase of MI. Knockout of RNF149, transplantation of <i>Rnf149</i><sup>-/-</sup> bone marrow, and bone marrow macrophage-specific RNF149-knockdown markedly exacerbated cardiac dysfunction in murine MI models. Conversely, overexpression of RNF149 in macrophages attenuated the ischemia-induced decline in cardiac contractile function. RNF149 deletion increased infiltration of proinflammatory monocytes/macrophages, accompanied by a hastened decline in reparative subsets, leading to aggravation of myocardial apoptosis and impairment of infarct healing. Our data revealed that RNF149 in infiltrated macrophages restricted inflammation by promoting ubiquitylation-dependent proteasomal degradation of IFNGR1 (interferon gamma receptor 1). Loss of IFNGR1 rescued deleterious effects of RNF149 deficiency on MI. We further demonstrated that STAT1 activation induced <i>Rnf149</i> transcription, which, in turn, destabilized the IFNGR1 protein to counteract type-II IFN (interferon) signaling, creating a feedback control mechanism to fine-tune macrophage-driven inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings highlight the significance of RNF149 as a molecular brake on macrophage response to MI and uncover a macrophage-intrinsic posttranslational mechanism essential for maintaining immune homeostasis and facilitating cardiac repair following MI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38989590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38989590</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324023>10.1161/CIRCRESAHA.123.324023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38989590</guid>
<pubDate>Thu, 11 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chun-Kai Huang</dc:creator>
<dc:creator>Zhiyong Chen</dc:creator>
<dc:creator>Zhongxing Zhou</dc:creator>
<dc:creator>Shuaijie Chen</dc:creator>
<dc:creator>Longqing Chen</dc:creator>
<dc:creator>Liliang Li</dc:creator>
<dc:creator>Tao Li</dc:creator>
<dc:creator>Xiaoxiang Yan</dc:creator>
<dc:creator>Dajun Chai</dc:creator>
<dc:date>2024-07-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>RNF149 Destabilizes IFNGR1 in Macrophages to Favor Post-Infarction Cardiac Repair</dc:title>
<dc:identifier>pmid:38989590</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324023</dc:identifier>
</item>
<item>
<title>Multimodal Imaging-Assisted Intravascular Theranostic Photoactivation on Atherosclerotic Plaque</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38989585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Optical coherence tomography-near-infrared fluorescence imaging-guided macrophage dectin-1-targetable photoactivation could induce the transition of macrophage/lipid-rich plaques into collagen-rich lesions through autophagy-mediated inflammation resolution and TGF-β-dependent fibrotic replacement. This novel strategy offers a new opportunity for the catheter-based theranostic strategy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 11. doi: 10.1161/CIRCRESAHA.123.323970. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis is a chronic inflammatory disease causing a fatal plaque rupture, and its key aspect is a failure to resolve inflammation. We hypothesize that macrophage-targeted near-infrared fluorescence emitting photoactivation could simultaneously assess macrophage/lipid-rich plaques in vivo and facilitate inflammation resolution.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: We fabricated a dectin-1-targeted photoactivatable theranostic agent through the chemical conjugation of the near-infrared fluorescence-emitting photosensitizer chlorin e6 and the dectin-1 ligand laminarin-chlorin e6. Intravascular photoactivation by a customized fiber-based diffuser after administration of laminarin-chlorin e6 effectively reduced inflammation in the targeted plaques of atherosclerotic rabbits in vivo as serially assessed by dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular catheter imaging after 4 weeks. The number of apoptotic macrophages peaked at 1 day after laser irradiation and then resolved until 4 weeks. Autophagy was strongly augmented 1 hour after the light therapy, with the formation of autophagolysosomes. Laminarin-chlorin e6 photoactivation increased the terminal deoxynucleotidyl transferase dUTP nick end labeling/RAM11- and MerTK (c-Mer tyrosine kinase)-positive cells in the plaques, suggesting enhanced efferocytosis. In line with inflammation resolution, photoactivation reduced the plaque burden through fibrotic replacement via the TGF (transforming growth factor)-β/CTGF (connective tissue growth factor) pathway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Optical coherence tomography-near-infrared fluorescence imaging-guided macrophage dectin-1-targetable photoactivation could induce the transition of macrophage/lipid-rich plaques into collagen-rich lesions through autophagy-mediated inflammation resolution and TGF-β-dependent fibrotic replacement. This novel strategy offers a new opportunity for the catheter-based theranostic strategy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38989585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38989585</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323970>10.1161/CIRCRESAHA.123.323970</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38989585</guid>
<pubDate>Thu, 11 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jin Hyuk Kim</dc:creator>
<dc:creator>Joon Woo Song</dc:creator>
<dc:creator>Yeon Hoon Kim</dc:creator>
<dc:creator>Hyun Jung Kim</dc:creator>
<dc:creator>Ryeong Hyun Kim</dc:creator>
<dc:creator>Ye Hee Park</dc:creator>
<dc:creator>Hyeong Soo Nam</dc:creator>
<dc:creator>Dong Oh Kang</dc:creator>
<dc:creator>Hongki Yoo</dc:creator>
<dc:creator>Kyeongsoon Park</dc:creator>
<dc:creator>Jin Won Kim</dc:creator>
<dc:date>2024-07-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Multimodal Imaging-Assisted Intravascular Theranostic Photoactivation on Atherosclerotic Plaque</dc:title>
<dc:identifier>pmid:38989585</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323970</dc:identifier>
</item>
<item>
<title>Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38989575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ARM and aortic rupture are uncommon after elective FB-EVAR of asymptomatic intact TAAAs. Half of the ARMs occurred early, and most of the late deaths were not aortic related. Late all-cause mortality rate and the need for secondary interventions were 46% and 40%, respectively, 5 years after FB-EVAR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.068234. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used as a minimally invasive alternative to open surgical repair to treat patients with thoracoabdominal aortic aneurysms (TAAAs). The aim of this study was to evaluate aortic-related mortality (ARM) and aortic aneurysm rupture after FB-EVAR of TAAAs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients enrolled in 8 prospective, nonrandomized, physician-sponsored investigational device exemption studies between 2005 and 2020 who underwent elective FB-EVAR of asymptomatic intact TAAAs were analyzed. Primary end points were ARM, defined as any early mortality (30 days or in hospital) or late mortality from aortic rupture, dissection, organ or limb malperfusion attributable to aortic disease, complications of reinterventions, or aortic rupture. Secondary end points were early major adverse events, TAAA life-altering events (defined as death, permanent spinal cord injury, permanent dialysis, or stroke), all-cause mortality, and secondary interventions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1109 patients were analyzed; 589 (53.1%) had extent I-III and 520 (46.9%) had extent IV TAAAs. Median age was 73.4 years (interquartile range, 68.1-78.3 years); 368 (33.2%) were women. Early mortality was 2.7% (n=30); congestive heart failure was associated with early mortality (odds ratio, 3.30 [95% CI, 1.22-8.02]; <i>P</i>=0.01). Incidence of early aortic rupture was 0.4% (n=4). Incidence of early major adverse events and TAAA life-altering events was 20.4% (n=226) and 7.7% (n=85), respectively. There were 30 late ARMs; 5-year cumulative incidence was 3.8% (95% CI, 2.6%-5.4%); older age and extent I-III TAAAs were independently associated with late ARM (each <i>P</i>&lt;0.05). Fourteen late aortic ruptures occurred; 5-year cumulative incidence was 2.7% (95% CI, 1.2%-4.3%); extent I-III TAAAs were associated with late aortic rupture (hazard ratio, 5.85 [95% CI, 1.31-26.2]; <i>P</i>=0.02). Five-year all-cause mortality was 45.7% (95% CI, 41.7%-49.4%). Five-year cumulative incidence of secondary intervention was 40.3% (95% CI, 35.8%-44.5%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ARM and aortic rupture are uncommon after elective FB-EVAR of asymptomatic intact TAAAs. Half of the ARMs occurred early, and most of the late deaths were not aortic related. Late all-cause mortality rate and the need for secondary interventions were 46% and 40%, respectively, 5 years after FB-EVAR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02089607, NCT02050113, NCT02266719, NCT02323581, NCT00583817, NCT01654133, NCT00483249, NCT02043691, and NCT01874197.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38989575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38989575</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068234>10.1161/CIRCULATIONAHA.123.068234</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38989575</guid>
<pubDate>Thu, 11 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gustavo S Oderich</dc:creator>
<dc:creator>Ying Huang</dc:creator>
<dc:creator>William S Harmsen</dc:creator>
<dc:creator>Emanuel R Tenorio</dc:creator>
<dc:creator>Andres Schanzer</dc:creator>
<dc:creator>Carlos H Timaran</dc:creator>
<dc:creator>Darren B Schneider</dc:creator>
<dc:creator>Bernardo C Mendes</dc:creator>
<dc:creator>Matthew J Eagleton</dc:creator>
<dc:creator>Mark A Farber</dc:creator>
<dc:creator>Warren J Gasper</dc:creator>
<dc:creator>Adam W Beck</dc:creator>
<dc:creator>Matthew P Sweet</dc:creator>
<dc:creator>W Anthony Lee</dc:creator>
<dc:creator>United States Aortic Research Consortium</dc:creator>
<dc:date>2024-07-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study</dc:title>
<dc:identifier>pmid:38989575</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068234</dc:identifier>
</item>
<item>
<title>Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38989565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.068587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. Variables and outcomes were defined according to the Society for Vascular Surgery reporting standards. Device modification and procedure details were collected and analyzed. Efficacy outcomes included technical success and safety outcomes included major adverse events and 30-day mortality. Follow-up outcomes included reinterventions, endoleaks, target vessel patency rates and overall and aortic-related mortality. Multivariable analysis was performed aiming at identifying predictors of technical success, 30-day mortality, and major adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 1274 patients were included in the study from 19 centers. Median age was 74 (IQR, 68-79), and 75.7% were men; 45.7% were complex abdominal aortic aneurysms, and 54.3% were thoracoabdominal aortic aneurysms; 65.5% patients presented electively, 24.6% were symptomatic, and 9.9% were ruptured. Most patients (83.1%) were submitted to a fenestrated repair, 3.6% to branched repair, and 13.4% to a combined fenestrated and branched repair. Most patients (85.8%) had ≥3 target vessels included. The overall technical success was 94% (94% in elective, 93.4% in symptomatic, and 95.1% in ruptured cases). Thirty-day mortality was 5.8% (4.1% in elective, 7.6% in symptomatic, and 12.7% in ruptured aneurysms). Major adverse events occurred in 25.2% of cases (23.1% in elective, 27.8% in symptomatic, and 30.3% in ruptured aneurysms). Median follow-up was 21 months (5.6-50.6). Freedom from reintervention was 73.8%, 61.8%, and 51.4% at 1, 3, and 5 years; primary target vessel patency was 96.9%, 93.6%, and 90.3%. Overall survival and freedom from aortic-related mortality was 82.4%/92.9%, 69.9%/91.6%, and 55.0%/89.1% at 1, 3, and 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38989565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38989565</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068587>10.1161/CIRCULATIONAHA.123.068587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38989565</guid>
<pubDate>Thu, 11 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nikolaos Tsilimparis</dc:creator>
<dc:creator>Ryan Gouveia E Melo</dc:creator>
<dc:creator>Emanuel R Tenorio</dc:creator>
<dc:creator>Salvatore Scali</dc:creator>
<dc:creator>Bernardo Mendes</dc:creator>
<dc:creator>Sukgu Han</dc:creator>
<dc:creator>Marc Schermerhorn</dc:creator>
<dc:creator>Donald J Adam</dc:creator>
<dc:creator>Mahmoud B Malas</dc:creator>
<dc:creator>Mark Farber</dc:creator>
<dc:creator>Tilo Kölbel</dc:creator>
<dc:creator>Benjamin Starnes</dc:creator>
<dc:creator>George Joseph</dc:creator>
<dc:creator>Daniela Branzan</dc:creator>
<dc:creator>Frederic Cochennec</dc:creator>
<dc:creator>Carlos Timaran</dc:creator>
<dc:creator>Luca Bertoglio</dc:creator>
<dc:creator>Enrico Cieri</dc:creator>
<dc:creator>Luís Mendes Pedro</dc:creator>
<dc:creator>Fabio Verzini</dc:creator>
<dc:creator>Adam W Beck</dc:creator>
<dc:creator>Jesse Chait</dc:creator>
<dc:creator>Alyssa Pyun</dc:creator>
<dc:creator>Gregory A Magee</dc:creator>
<dc:creator>Nicholas Swerdlow</dc:creator>
<dc:creator>Maciej Juszczak</dc:creator>
<dc:creator>Andrew Barleben</dc:creator>
<dc:creator>Rohini Patel</dc:creator>
<dc:creator>Vivian C Gomes</dc:creator>
<dc:creator>Giuseppe Panuccio</dc:creator>
<dc:creator>Matthew P Sweet</dc:creator>
<dc:creator>Sara L Zettervall</dc:creator>
<dc:creator>Jean-Pierre Becquemin</dc:creator>
<dc:creator>Jennifer Canonge</dc:creator>
<dc:creator>Jésus Porras-Colón</dc:creator>
<dc:creator>Marina Dias-Neto</dc:creator>
<dc:creator>Antonino Giordano</dc:creator>
<dc:creator>Gustavo S Oderich</dc:creator>
<dc:date>2024-07-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair</dc:title>
<dc:identifier>pmid:38989565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068587</dc:identifier>
</item>
<item>
<title>Consequences of ionizing radiation exposure to the cardiovascular system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38987578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>Ionizing radiation is widely used in various industrial and medical applications, resulting in increased exposure for certain populations. Lessons from radiation accidents and occupational exposure have highlighted the cardiovascular and cerebrovascular risks associated with radiation exposure. In addition, radiation therapy for cancer has been linked to numerous cardiovascular complications, depending on the distribution of the dose by volume in the heart and other relevant target tissues in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 10. doi: 10.1038/s41569-024-01056-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ionizing radiation is widely used in various industrial and medical applications, resulting in increased exposure for certain populations. Lessons from radiation accidents and occupational exposure have highlighted the cardiovascular and cerebrovascular risks associated with radiation exposure. In addition, radiation therapy for cancer has been linked to numerous cardiovascular complications, depending on the distribution of the dose by volume in the heart and other relevant target tissues in the circulatory system. The manifestation of symptoms is influenced by numerous factors, and distinct cardiac complications have previously been observed in different groups of patients with cancer undergoing radiation therapy. However, in contemporary radiation therapy, advances in treatment planning with conformal radiation delivery have markedly reduced the mean heart dose and volume of exposure, and these variables are therefore no longer sole surrogates for predicting the risk of specific types of heart disease. Nevertheless, certain cardiac substructures remain vulnerable to radiation exposure, necessitating close monitoring. In this Review, we provide a comprehensive overview of the consequences of radiation exposure on the cardiovascular system, drawing insights from various cohorts exposed to uniform, whole-body radiation or to partial-body irradiation, and identify potential risk modifiers in the development of radiation-associated cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38987578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38987578</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01056-4>10.1038/s41569-024-01056-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38987578</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>James W S Jahng</dc:creator>
<dc:creator>Mark P Little</dc:creator>
<dc:creator>Hyunsoo J No</dc:creator>
<dc:creator>Billy W Loo</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Consequences of ionizing radiation exposure to the cardiovascular system</dc:title>
<dc:identifier>pmid:38987578</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01056-4</dc:identifier>
</item>
<item>
<title>Sustained Intraprocedural Cardiac Arrest During BASILICA TAVR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>The bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) procedure allows patients with severe aortic stenosis and anatomical challenges from aortic leaflet orientation, positioning of coronary ostia, and height of sinuses of Valsalva to undergo TAVR. We present a case of intraprocedural cardiac arrest secondary to iatrogenic left main coronary artery obstruction following a successful BASILICA procedure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):317-321. doi: 10.1016/j.jacc.2024.05.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) procedure allows patients with severe aortic stenosis and anatomical challenges from aortic leaflet orientation, positioning of coronary ostia, and height of sinuses of Valsalva to undergo TAVR. We present a case of intraprocedural cardiac arrest secondary to iatrogenic left main coronary artery obstruction following a successful BASILICA procedure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986674</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.021>10.1016/j.jacc.2024.05.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986674</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Morgan R Casper</dc:creator>
<dc:creator>Garrett Cohen</dc:creator>
<dc:creator>Benjamin Stripe</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sustained Intraprocedural Cardiac Arrest During BASILICA TAVR</dc:title>
<dc:identifier>pmid:38986674</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.021</dc:identifier>
</item>
<item>
<title>Geographic Disparities in Access to Cardiologists in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):315-316. doi: 10.1016/j.jacc.2024.04.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986673</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.054>10.1016/j.jacc.2024.04.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986673</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeong Hwan Kim</dc:creator>
<dc:creator>Trinidad Cisneros</dc:creator>
<dc:creator>Amanda Nguyen</dc:creator>
<dc:creator>Jeroen van Meijgaard</dc:creator>
<dc:creator>Haider J Warraich</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Geographic Disparities in Access to Cardiologists in the United States</dc:title>
<dc:identifier>pmid:38986673</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.054</dc:identifier>
</item>
<item>
<title>The Role of Psychosocial Stress on Cardiovascular Disease in Women: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>Psychosocial stress can affect cardiovascular health through multiple pathways. Certain stressors, such as socioeconomic disadvantage, childhood adversity, intimate partner violence, and caregiving stress, are especially common among women. The consequences of stress begin at a young age and persist throughout the life course. This is especially true for women, among whom the burden of negative psychosocial experiences tends to be larger in young age and midlife. Menarche, pregnancy, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):298-314. doi: 10.1016/j.jacc.2024.05.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Psychosocial stress can affect cardiovascular health through multiple pathways. Certain stressors, such as socioeconomic disadvantage, childhood adversity, intimate partner violence, and caregiving stress, are especially common among women. The consequences of stress begin at a young age and persist throughout the life course. This is especially true for women, among whom the burden of negative psychosocial experiences tends to be larger in young age and midlife. Menarche, pregnancy, and menopause can further exacerbate stress in vulnerable women. Not only is psychosocial adversity prevalent in women, but it could have more pronounced consequences for cardiovascular risk among women than among men. These differential effects could reside in sex differences in responses to stress, combined with women's propensity toward vasomotor reactivity, microvascular dysfunction, and inflammation. The bulk of evidence suggests that targeting stress could be an important strategy for cardiovascular risk reduction in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986672</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.016>10.1016/j.jacc.2024.05.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986672</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Imo A Ebong</dc:creator>
<dc:creator>Odayme Quesada</dc:creator>
<dc:creator>Ida T Fonkoue</dc:creator>
<dc:creator>Deirdre Mattina</dc:creator>
<dc:creator>Samaah Sullivan</dc:creator>
<dc:creator>Glaucia Maria Moraes de Oliveira</dc:creator>
<dc:creator>Telisa Spikes</dc:creator>
<dc:creator>Jyoti Sharma</dc:creator>
<dc:creator>Yvonne Commodore</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Niti R Aggarwal</dc:creator>
<dc:creator>Viola Vaccarino</dc:creator>
<dc:creator>American College of Cardiology Cardiovascular Disease in Women Committee</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Role of Psychosocial Stress on Cardiovascular Disease in Women: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38986672</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.016</dc:identifier>
</item>
<item>
<title>Revascularization Strategies in Patients With MI and MVD: Have We Got the Answers?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):295-297. doi: 10.1016/j.jacc.2024.05.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986671</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.019>10.1016/j.jacc.2024.05.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986671</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Adrian P Banning</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Revascularization Strategies in Patients With MI and MVD: Have We Got the Answers?</dc:title>
<dc:identifier>pmid:38986671</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.019</dc:identifier>
</item>
<item>
<title>Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Complete revascularization following MI reduces all-cause mortality, cardiovascular mortality, MI, major adverse cardiac events, and repeat revascularization. There may be benefits to immediate complete revascularization, but additional head-to-head trials are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):276-294. doi: 10.1016/j.jacc.2024.04.051.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Complete revascularization with percutaneous coronary intervention improves outcomes compared with culprit revascularization following myocardial infarction (MI) with multivessel coronary artery disease. An all-cause mortality reduction has never been demonstrated. Debate also remains regarding the optimal timing of complete revascularization (immediate or staged), and method of evaluation of nonculprit lesions (physiology or angiography).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to perform an updated systematic review with frequentist and Bayesian network meta-analyses including the totality of randomized data investigating revascularization strategies in patients presenting with MI and multivessel coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The primary comparison tested complete vs culprit revascularization. Timing and methods of achieving complete revascularization were assessed. The prespecified primary outcome was all-cause mortality. Outcomes were expressed as relative risk (RR) (95% CI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Twenty-four eligible trials randomized 16,371 patients (weighted mean follow-up: 26.4 months). Compared with culprit revascularization, complete revascularization reduced all-cause mortality in patients with any MI (RR: 0.85; 95% CI: 0.74-0.99; P = 0.04). Cardiovascular mortality, MI, major adverse cardiac events and repeat revascularization were also significantly reduced. In patients presenting with ST-segment elevation myocardial infarction, the point estimate for all-cause mortality with complete revascularization was RR: 0.91 (95% CI: 0.78-1.05; P = 0.18). Rates of stent thrombosis, major bleeding, and acute kidney injury were similar. Immediate complete revascularization ranked higher than staged complete revascularization for all endpoints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Complete revascularization following MI reduces all-cause mortality, cardiovascular mortality, MI, major adverse cardiac events, and repeat revascularization. There may be benefits to immediate complete revascularization, but additional head-to-head trials are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986670</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.051>10.1016/j.jacc.2024.04.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986670</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohin K Reddy</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Yasser Jamil</dc:creator>
<dc:creator>Mahesh V Madhavan</dc:creator>
<dc:creator>Michael G Nanna</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis</dc:title>
<dc:identifier>pmid:38986670</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.051</dc:identifier>
</item>
<item>
<title>Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):273-275. doi: 10.1016/j.jacc.2024.04.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986669</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.052>10.1016/j.jacc.2024.04.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986669</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Usman Baber</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?</dc:title>
<dc:identifier>pmid:38986669</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.052</dc:identifier>
</item>
<item>
<title>Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986668/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):244-246. doi: 10.1016/j.jacc.2024.05.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986668/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986668</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.018>10.1016/j.jacc.2024.05.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986668</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Maya Guglin</dc:creator>
<dc:creator>Dustin Hillerson</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities</dc:title>
<dc:identifier>pmid:38986668</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.018</dc:identifier>
</item>
<item>
<title>Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38986667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240712222744&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Racial and ethnic differences exist in baseline characteristics of persons affected by DbCM, with Black and Hispanic study participants demonstrating higher risk features. These insights inform the need to address differences in the population with DbCM. (Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy [ARISE-HF]; NCT04083339).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 16;84(3):233-243. doi: 10.1016/j.jacc.2024.04.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetic cardiomyopathy (DbCM) increases risk of overt heart failure in individuals with diabetes mellitus. Racial and ethnic differences in DbCM remain unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to identify racial and ethnic differences among individuals with type 2 diabetes mellitus, structural heart disease, and impaired exercise capacity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ARISE-HF (Aldolase Reductase Inhibitor for Stabilization of Exercise Capacity in Heart Failure) trial is assessing the efficacy of an aldose reductase inhibitor for exercise capacity preservation in 691 persons with DbCM. Baseline characteristics, echocardiographic parameters, and functional capacity were analyzed and stratified by race and ethnicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age of the study participants was 67.4 years; 50% were women. Black and Hispanic patients had lower use of diabetes mellitus treatments. Black patients had poorer baseline ventricular function and more impaired global longitudinal strain. Overall, health status was preserved, based on Kansas City Cardiomyopathy Questionnaire scores, but reduced exercise capacity was present as evidenced by reduced Physical Activity Scale for the Elderly (PASE) scores. When stratified by race and ethnicity and compared with the entire cohort, Black patients had poorer health status, more reduced physical activity, and a greater impairment in exercise capacity during cardiopulmonary exercise testing, whereas Hispanic patients also displayed compromised cardiopulmonary exercise testing functional capacity. White patients demonstrated higher physical activity and functional capacity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Racial and ethnic differences exist in baseline characteristics of persons affected by DbCM, with Black and Hispanic study participants demonstrating higher risk features. These insights inform the need to address differences in the population with DbCM. (Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy [ARISE-HF]; NCT04083339).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38986667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240712222744&v=2.18.0.post9+e462414">38986667</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.053>10.1016/j.jacc.2024.04.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38986667</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jose Lopez</dc:creator>
<dc:creator>Yuxi Liu</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Stefano Del Prato</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Thomas H Marwick</dc:creator>
<dc:creator>Julio Rosenstock</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Riccardo Perfetti</dc:creator>
<dc:creator>Alessia Urbinati</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Nasrien E Ibrahim</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial</dc:title>
<dc:identifier>pmid:38986667</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.053</dc:identifier>
</item>





























</channel>
</rss>